司库奇尤单抗治疗后出现严重的新发溃疡性结肠炎。
Severe de novo Ulcerative Colitis following Ixekizumab Therapy.
作者信息
Philipose Jobin, Ahmed Moiz, Idiculla Pretty S, Mulrooney Stephen M, Gumaste Vivek V
机构信息
Department of Internal Medicine, Staten Island University Hospital, Northwell Health, New York, New York, USA.
Department of Gastroenterology, Mount Sinai School of Medicine, Elmhurst Hospital Center, New York, New York, USA.
出版信息
Case Rep Gastroenterol. 2018 Oct 17;12(3):617-621. doi: 10.1159/000493922. eCollection 2018 Sep-Dec.
Ixekizumab is a selective monoclonal antibody targeting interleukin-17A, approved for the treatment of chronic plaque psoriasis. It has rarely been associated with inflammatory bowel disease (IBD) in randomized trials only. We report a unique case of severe new-onset ulcerative colitis in a young male complicated by cytomegalovirus infection who was on ixekizumab therapy for plaque psoriasis. We recommend that clinicians should exercise caution before prescribing ixekizumab as it seems to induce and exacerbate IBD.
司库奇尤单抗是一种靶向白细胞介素-17A的选择性单克隆抗体，已被批准用于治疗慢性斑块状银屑病。仅在随机试验中，它很少与炎症性肠病（IBD）相关。我们报告了一例独特的病例，一名年轻男性在接受司库奇尤单抗治疗斑块状银屑病时，发生了严重的新发溃疡性结肠炎，并伴有巨细胞病毒感染。我们建议临床医生在开具司库奇尤单抗处方前应谨慎，因为它似乎会诱发和加重IBD。
Zotero 插件